about
Discordance of Global Assessments by Patient and Physician Is Higher in Female than in Male Patients Regardless of the Physician's Sex: Data on Patients with Rheumatoid Arthritis, Axial Spondyloarthritis, and Psoriatic Arthritis from the DANBIO RegiMicroalbuminuria in patients with rheumatoid arthritisAnkylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry.Impact of tobacco smoking on response to tumour necrosis factor-alpha inhibitor treatment in patients with ankylosing spondylitis: results from the Danish nationwide DANBIO registry.Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO.Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry.Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry.Validity and completeness of rheumatoid arthritis diagnoses in the nationwide DANBIO clinical register and the Danish National Patient Registry.Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care.Cardiac performance and thyroid function. The correlation between systolic time intervals, heart rate and thyroid hormone levels.Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides – a follow-up study from the DANBIO RegistryTo switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry[Lactic acidosis in non-Hodgkin lymphoma][Compulsory military service. Stress reactions during military service][Munchhausen's syndrome. A retrospective account of the resources employed]The effects of propranolol and verapamil on hyperthyroid heart symptoms and function, assessed by systolic time intervalsVariations in blood viscosity in patients with acute cardiogenic pulmonary oedema treated with frusemide[Kidney function problems in rheumatoid arthritis][ECG changes in pheochromocytoma][Needles for bone marrow examination]Captopril and resistant ascites[Schnitzler syndrome is a diagnostic challenge]Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching' by Cantini and BenucciResponse to ''To switch or not to switch': the missing piece in the puzzle of biosimilar literature?' by Scherlinger et al
P50
Q30984432-6F12EC00-6EC6-40EC-926F-FBEAD9CE6A88Q33567099-AD971016-2664-4728-9024-7C39F423C9E0Q39138037-A862C109-A64D-46C8-9404-012D2AF56E9BQ40214597-0E8E95EF-CC9D-4F94-9DAE-B8224846A008Q40251018-30FC6F90-7DD6-40E4-ADE6-E4AD1F6BBF46Q42210089-B507B504-79E0-4310-9D34-D6E5F25A1650Q45229094-911B63BC-FE5E-4AFA-AA93-67574B2383E6Q46893265-000109B5-309C-42F7-A7E6-F84E8F579AD1Q47104450-DF78ECF6-4EEA-4FC4-8EDA-BEF08E7BB32BQ50135901-7F0EA97F-67D3-4EF1-8437-8B18C31DB84EQ52391529-22AB6117-BF87-4BD5-AA0B-99A4842B19A4Q56973995-3829E558-A817-467E-8712-2CC8C18B4E0DQ58609284-A27977EF-45C7-41E9-B727-BEC7ACDB6559Q69836687-C4C2085C-60D8-4950-9C81-1FDFDAD72BBDQ70497430-F785C9E6-BBA7-450E-9A23-B5D2AC89E010Q70724841-91279994-E071-4D2E-8481-4A9BE879106DQ70728136-CB22482C-DA10-464F-9DCE-289EC32413F4Q71084127-FC19693E-B584-4BD2-8FA9-2EA6761DD749Q71206436-96074CC0-B0C8-41B0-9C5A-FC490F3D291FQ71341676-7B74F456-75E6-4711-9C6B-F8A719E5B613Q72010969-7E71D6CE-E073-4AA7-ABA0-F1F8A5D278E0Q72558369-0F9BF903-6623-4599-8D17-2F0AF90FF154Q85714353-37D715E7-8BBB-46C6-8A7A-907C5F063BC8Q90681067-D66D17D8-C5A0-4282-B1CF-9FFF745E240CQ91185122-4FDA56DB-8C4E-42EC-8D81-776AB6E6371A
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Henrik Nordin
@ast
Henrik Nordin
@en
Henrik Nordin
@es
Henrik Nordin
@nl
Henrik Nordin
@sl
type
label
Henrik Nordin
@ast
Henrik Nordin
@en
Henrik Nordin
@es
Henrik Nordin
@nl
Henrik Nordin
@sl
prefLabel
Henrik Nordin
@ast
Henrik Nordin
@en
Henrik Nordin
@es
Henrik Nordin
@nl
Henrik Nordin
@sl
P106
P21
P31
P496
0000-0002-5575-4454